Kutane vaskulære toksiciteter, herunder vaskulær ulceration og gangræn, er opstået hos patienter med myeloproliferative sygdomme under behandling med hydroxycarbamid.
Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide.